Targeted therapy-induced radiation recall

Lévy, Antonin; Hollebecque, Antoine; Bourgier, C.; Loriot, Yohann; Guigay, J.; Robert, Caroline; Delaloge, Suzette; Bahleda, Rastislav; Massard, Christophe; Soria, Jean‐Charles; Deutsch, Éric

doi:10.1016/j.ejca.2012.12.009

Cited by 59 publications

(38 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…New targeted therapies do affect the skin in very specific ways. Interestingly, cases of erlotinib-induced radiation recall dermatitis were described in the literature [12,18]. This observation suggests that targeted therapies, particularly tyrosine kinase inhibitors, should be added to the list of radiation recall dermatitis-inducing substances.…”

Section: Discussionmentioning

confidence: 99%

Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature

Conen¹,

Mosna-Firlejczyk²,

Rochlitz³

et al. 2014

Dermatology

View full text Add to dashboard Cite

The cutaneous effects of BRAF (serine/threonine protein kinase B-raf) inhibitors such as vemurafenib remain poorly defined. Rash, squamous cell carcinoma, keratoacanthoma and photosensitivity are the most common grade 2 or 3 adverse events observed in clinical trials. We here report the case of a patient with a BRAF V600E mutated metastatic melanoma who developed severe radiation recall dermatitis 6 weeks after completing radiotherapy. Vemurafenib treatment had been initiated 1 week before the development of dermatitis because of rapidly progressing disease. Upon topical treatment of the affected skin areas, clinical symptoms regressed over a period of 2 months, although vemurafenib was continuously administered. As our case goes in line with other reports, we believe that physicians should be aware of this additional cutaneous side effect of vemurafenib and that continuation of the treatment is safe when close clinical control and interdisciplinary management can be provided.

show abstract

Section: Discussionmentioning

confidence: 99%

Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature

Conen¹,

Mosna-Firlejczyk²,

Rochlitz³

et al. 2014

Dermatology

View full text Add to dashboard Cite

show abstract

“…Baroudjian et al [51] describe the occurrence of radiodermatitis (CTCAE grade 2-3) after vemurafenib followed by radiotherapy of the right axillary area and the radiosensitizing effect of vemurafenib has even been connected with the development of a hemopneumothorax. Skin reactions which were classified as radiation recall phenomena and occurred only after vemurafenib with preceding radiotherapy have been documented as a single case each by Levy et al [53] as radiodermatitis, by Wang et al [54] as keratosis pilaris-like dermatitis, by Conen et al [55] as a maculopapular rash with edema and severe erythema and by Braunstein et al [56] as a serious case of ulceration with parallel erythema and scar dehiscence that required vemurafenib discontinuation. In two cases described by Boussemart et al [57] the sequential application of radiotherapy and vemurafenib to treat cutaneous and bone metastases led to the development of delayed skin reactions in the form of a pruriginous erythematous vesicles or a pruriginous rectangular dermatitis.…”

Section: Braf V600 Inhibitors and Radiotherapy Of Nonbrain Metastasismentioning

confidence: 99%

“…The start of vemurafenib between 1 and 42 days (median: 21 days) after the end of radiotherapy has been strongly associated with the occurrence of radiation recall phenomena. Delayed skin reactions classified as radiation recall radiodermatitis were usually observed between 7 and 14 days (median: 7.5 days) after the start of vemurafenib administration [53][54][55][56][57]. Radiation recall cutis verticis gyrata after radiation treatment of the scalp occurred later, between 14 and 28 days (median: 21 days) after start of BRAF inhibitor therapy which had been preceded by whole-brain radiotherapy [62][63]67].…”

Section: Impact Of Dose and Sequence Of Radiation And Braf V600 Inhibitormentioning

confidence: 99%

Radiotherapy with BRAF Inhibitor Therapy for Melanoma: Progress and Possibilities

et al. 2015

View full text Add to dashboard Cite

The introduction of small molecule BRAF(V600) kinase inhibitors represents a milestone in the targeted therapy of patients with metastatic melanoma by a significant increase in therapeutic efficacy in terms of overall and progression-free survival compared with conventional chemotherapy. Beside BRAF(V600) inhibitor treatment, radiotherapy is a further mainstay for the therapy of metastatic melanoma and thus a concomitant or sequential application of BRAF(V600) inhibitors and radiotherapy is inevitable. Recent reports show a significant radiosensitization of the irradiated healthy tissue in patients with melanoma after the combination of radiotherapy and BRAF(V600) inhibitors, evoking concern in clinical practice. We review interactions of BRAF(V600) inhibitors and radiation with regard to antitumor effects and an increased radiotoxicity in the healthy tissue.

show abstract

“…Une réaction inflammatoire en zone irradiée peut apparaître chez les patients déjà irradiés [93]. Une réaction inflammatoire en zone irradiée peut apparaître chez les patients déjà irradiés [93].…”

Section: Complications Et Séquelles Des Thérapies Ciblées Autres Que unclassified

Effets secondaires, complications et séquelles de la chimiothérapie

Moal¹

2013

Complications Et Séquelles Des Traitements en Cancérologie ORL

View full text Add to dashboard Cite

Targeted therapy-induced radiation recall

Cited by 59 publications

References 32 publications

Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature

Vemurafenib-Induced Radiation Recall Dermatitis: Case Report and Review of the Literature

Radiotherapy with BRAF Inhibitor Therapy for Melanoma: Progress and Possibilities

Effets secondaires, complications et séquelles de la chimiothérapie

Contact Info

Product

Resources

About